Opendata, web and dolomites


Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection

Total Cost €


EC-Contrib. €






 mfloDx project word cloud

Explore the words cloud of the mfloDx project. It provides you a very rough idea of what is the project "mfloDx" about.

million    patients    detection    expenditure    tests    world    strains    tools    rate    market    96    infects    diagnostics    92    life    frac14    prescriptions    spread    molecular    identification    treatment    tbplus    diagnoses    rapid    population    bacteria    organization    suggest    alarming    killed    spreading    2030    recommend    people    100    2024    faulty    estimates    grow    six    thousands    antibiotic    addressable    2015    trained    incorrect    hours    specificity    prescription    close    costly    prevent    point    recommended    undergo    countries    forms    2000    treat    15    diagnostic    time    treatments    projected    billion    983    thereby    drug    tens    income    pilot    resistant    inappropriate    tb    times    mdr    tuberculosis    flourishing    reduce    urgently    mid    power    commercial    unnecessary    efficiency    global    stop    patient    euros    generation    33    months    minimdr    health    appropriate    showed    accurate    32k    diagnosis    curtail    platform    care    mflodx    worldwide    infections    incomplete    antibiotics    regimens    afflicted    lag    untreatable    suffering    first   

Project "mfloDx" data sheet

The following table provides information about the project.


Organization address
postcode: 171 65
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMPE DIAGNOSTICS AB SE (STOCKHOLM) coordinator 50˙000.00


 Project objective

Tuberculosis (TB) killed 33 million people worldwide in 2000-2015 and infects an estimated ¼ of the world population. Drug-resistant forms of TB are flourishing at an alarming rate due to faulty diagnosis and widespread prescription of incorrect antibiotics. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of untreatable TB forms. Simple, low cost diagnostic tools are needed to enable point-of-care testing in low- and mid-income countries. mfloDx is a low-cost, simple diagnostic platform that can identify close to 100% of drug resistant TB cases. Pilot tests of the first product, miniMDR-TB, showed the efficiency and specificity to be 92-96% in agreement with that of another molecular test recommended by the World Health Organization. Our next-generation mfloDx products, MDR-TB and MDR-TBplus, are expected to have close to 100% MDR-TB identification power. The low cost of mfloDx tests will enable market uptake in highly afflicted developing countries, and thereby help to stop the loss of life, the spread of antibiotic-resistant infections, and prevent unnecessary costs. Projected global expenditure on diagnosis and treatment of TB will reach €983 billion between 2015-2030. The addressable market for TB diagnostics is projected to grow to €3.1 billion by 2024. Available commercial diagnostics for MDR-TB often deliver incomplete diagnoses and require long lag times, costly equipment (€15-32K), and highly trained personnel to recommend prescriptions. As a result, less than one-third of new TB patients undergo testing to determine appropriate antibiotic treatments. Our estimates suggest that mfloDx would reduce the treatment costs per MDR-TB patient by tens of thousands of euros and diagnosis time from about six months to two hours. This would avoid costly and inappropriate antibiotic regimens, reduce patient suffering, and curtail the spread of drug-resistant bacteria.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MFLODX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MFLODX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

LTS (2020)


Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More